NASDAQ · STTK
Shattuck Labs, Inc.
$5.72-$0.09 (-1.46%)
Shattuck Labs, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.33% below the high.
Loading market information…
NASDAQ · CSBR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Champions Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Champions Oncology, Inc.’s next earnings report is currently expected on Dec 15, 2026, with estimated earnings per share of $0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Champions Oncology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2025 | Jul 23, 2025 | -$0.13+35.0% vs estimate | $12.36M+2.96% vs estimate |
|---|
| Q3 2025 | Mar 11, 2025 | $0.31+3,200.0% vs estimate | $17.04M+32.09% vs estimate |
|---|
| Q2 2025 | Dec 11, 2024 | $0.05+400.0% vs estimate | $13.50M+3.42% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.72-$0.09 (-1.46%)
Shattuck Labs, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.33% below the high.
$1.72-$0.02 (-0.87%)
InflaRx N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.86% below the high.
$4.23-$0.05 (-1.05%)
Artiva Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.89% below the high.
$4.23+$0.07 (+1.68%)
Oramed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.67% below the high.
$9.14-$0.15 (-1.61%)
Sutro Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.16% below the high.
$8.53-$0.13 (-1.5%)
Atara Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.46% below the high.
$0.84-$0.01 (-1.17%)
Connect Biopharma Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 78.13% below the high.
$2.13+$0.12 (+5.97%)
Kalaris Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 82.07% below the high.
